Pediatric Nephrology

, 26:2179 | Cite as

Distinct metalloproteinase excretion patterns in focal segmental glomerulosclerosis

  • Kimberly A. CzechEmail author
  • Michael Bennett
  • Prasad Devarajan
Original Article


Metalloproteinase-2 (MMP-2) and metalloproteinase-9 (MMP-9) degrade type IV collagen, and represent important tissue remodeling enzymes in several kidney disorders. In this study, we measured urinary levels of MMP-2, MMP-9, and the tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in patients with steroid-sensitive nephrotic syndrome (SSNS, n = 18, median age 5) and focal segmental glomerulosclerosis (FSGS, n = 16, median age 15). We found that urinary concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2 were significantly elevated in FSGS patients as compared to SSNS in both relapse and remission (p < 0.002). Furthermore, urinary levels of these enzymes are increased early on in the FSGS disease process (chronic kidney disease stages 1 and 2). The findings from this pilot study suggest that MMPs and TIMPs have the potential to represent candidate, early non-invasive biomarkers for diagnosis and/or response to therapy. In addition, they may represent therapeutic targets for preventing chronic kidney disease progression in FSGS.


Metalloproteinase Nephrotic syndrome Biomarker Tissue remodeling Chronic kidney disease Urinary proteins 


  1. 1.
    Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA (2009) Management of childhood onset nephrotic syndrome. Pediatrics 124:747–757PubMedCrossRefGoogle Scholar
  2. 2.
    Mendoza SA, Tune BM (1992) Treatment of childhood nephrotic syndrome. J Am Soc Nephrol 3:889–894PubMedGoogle Scholar
  3. 3.
    Hodson EM, Alexander SI (2008) Evaluation and management of steroid-sensitive nephrotic syndrome. Curr Opin Pediatr 20:145–150PubMedCrossRefGoogle Scholar
  4. 4.
    McBryde KD, Kershaw DB, Smoyer WE (2001) Pediatric steroid-resistant nephrotic syndrome. Curr Probl Pediatr Adolesc Health Care 31:280–307PubMedGoogle Scholar
  5. 5.
    Keeling J, Herrera GA (2008) Human matrix metalloproteinases: characteristics and pathologic role in altering mesangial homeostasis. Microsc Res Tech 71:371–379PubMedCrossRefGoogle Scholar
  6. 6.
    Catania JM, Chen G, Parrish AR (2007) Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292:F905–F911PubMedCrossRefGoogle Scholar
  7. 7.
    Tallant C, Marrero A, Gomis-Rüth FX (2010) Matrix metalloproteinases: fold and function of their catalytic domains. Biochim Biophys Acta 1803:20–28PubMedCrossRefGoogle Scholar
  8. 8.
    Thrailkill KM, Clay Bunn R, Fowlkes JL (2009) Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocr 35:1–10CrossRefGoogle Scholar
  9. 9.
    Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, Lian JD (2006) Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 366:243–248PubMedCrossRefGoogle Scholar
  10. 10.
    Turck J, Pollock AS, Lee LK, Marti HP, Lovett DH (1996) Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 271:15074–15083PubMedCrossRefGoogle Scholar
  11. 11.
    Liu WH, Tang NN, Zhang QD (2009) Could mycophenolate mofetil combined with benazepril delay tubulointerstitial fibrosis in 5/6 nephrectomized rats? Chin Med J (Engl) 122:199–204Google Scholar
  12. 12.
    Bauvois B, Mothu N, Nguyen J, Nguyen-Khoa T, Nöel LH, Jungers P (2007) Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis. Nephrol Dial Transplant 22:1115–1122PubMedCrossRefGoogle Scholar
  13. 13.
    Uchio-Yamada K, Manabe N, Goto Y, Anann S, Yamamoto Y, Takano K, Ogura A, Matsuda J (2005) Decreased expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in the kidneys of hereditary nephrotic (ICGN) mice. J Vet Med Sci 67:35–41PubMedCrossRefGoogle Scholar
  14. 14.
    Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, van Goor H, Kreutz R (2006) Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension. J Pharmacol Exp Ther 316:8–16PubMedCrossRefGoogle Scholar
  15. 15.
    Liu S, Li Y, Zhao H, Chen D, Huang Q, Wang S, Zou W, Zhang Y, Li X, Huang H (2006) Increase in extracellular cross-linking by tissue transglutaminase and reduction in expression of MMP-9 contribute differentially to focal segmental glomerulosclerosis in rats. Mol Cell Biochem 284:9–17PubMedCrossRefGoogle Scholar
  16. 16.
    Urushihara M, Kagami S, Kuhara T, Tamaki T, Kuroda Y (2002) Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis. Nephrol Dial Transplant 17:1189–1196PubMedCrossRefGoogle Scholar
  17. 17.
    Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637PubMedCrossRefGoogle Scholar
  18. 18.
    Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children (1978) Kidney Int 13:159–65Google Scholar
  19. 19.
    Wasilewska AM, Zoch-Zwierz WM (2008) Urinary levels of matrix metalloproteinases and their tissue inhibitors in nephrotic children. Pediatr Nephrol 23:1795–1802PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2011

Authors and Affiliations

  • Kimberly A. Czech
    • 1
    Email author
  • Michael Bennett
    • 1
  • Prasad Devarajan
    • 1
  1. 1.Division of Nephrology & HypertensionCincinnati Children’s Hospital and Medical CenterCincinnatiUSA

Personalised recommendations